The U.S. Department of Defense allocated $6 million to the University of Illinois Chicago to develop a potential treatment targeting COIVD-19. The development effort will…
A TrialSite community member shared a Rockville, Maryland-based venture’s positive Phase 2 results from a couple of months ago, which merited attention. Cerecor was founded…
Korea’s drug regulatory body extended the use of a stem cell therapy for COVID-19 for an additional year, allowing local hospitals to use the Pharmicell…
National Jewish Health capitalized on its network of connections to join a clinical trial investigating a drug that targets the inflammation-causing protein called NLRP3. The study,…
A novel cancer drug known as EXO-CD24 developed and tested at Tel Aviv Sourasky Medical Center (Ichilov Hospital), demonstrates promising results. Led by Professor Nadir…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
